These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 17404103

  • 1. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
    Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF.
    Clin Cancer Res; 2007 Apr 01; 13(7):2191-8. PubMed ID: 17404103
    [Abstract] [Full Text] [Related]

  • 2. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK.
    Clin Cancer Res; 2005 Jul 01; 11(13):4923-33. PubMed ID: 16000591
    [Abstract] [Full Text] [Related]

  • 3. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 01; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS.
    Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753
    [Abstract] [Full Text] [Related]

  • 5. Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin.
    Olivero M, Ruggiero T, Saviozzi S, Rasola A, Coltella N, Crispi S, Di Cunto F, Calogero R, Di Renzo MF.
    Mol Cancer Ther; 2006 May 15; 5(5):1126-35. PubMed ID: 16731744
    [Abstract] [Full Text] [Related]

  • 6. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors.
    Indraccolo S, Habeler W, Tisato V, Stievano L, Piovan E, Tosello V, Esposito G, Wagner R, Uberla K, Chieco-Bianchi L, Amadori A.
    Cancer Res; 2002 Nov 01; 62(21):6099-107. PubMed ID: 12414634
    [Abstract] [Full Text] [Related]

  • 7. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
    Yuan Z, Yan F, Wang YS, Liu HY, Gou LT, Zhao XY, Lai ST, Deng HX, Li J, Ding ZY, Xiong SQ, Kan B, Mao YQ, Chen LJ, Wei YQ, Zhao X.
    Cancer Chemother Pharmacol; 2009 Dec 01; 65(1):13-25. PubMed ID: 19387645
    [Abstract] [Full Text] [Related]

  • 8. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A.
    Clin Cancer Res; 2011 Apr 15; 17(8):2350-60. PubMed ID: 21220476
    [Abstract] [Full Text] [Related]

  • 9. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
    Liao Y, Zou YY, Xia WY, Hung MC.
    Cancer Gene Ther; 2004 Sep 15; 11(9):594-602. PubMed ID: 15272313
    [Abstract] [Full Text] [Related]

  • 10. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
    Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H.
    Biochem Pharmacol; 2006 Oct 16; 72(8):941-8. PubMed ID: 16934227
    [Abstract] [Full Text] [Related]

  • 11. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V, Blanárová O, Svihálková-Sindlerová L, Soucek K, Hofmanová J, Sova P, Kroutil A, Fedorocko P, Kozubík A.
    Gynecol Oncol; 2006 Jul 16; 102(1):32-40. PubMed ID: 16364413
    [Abstract] [Full Text] [Related]

  • 12. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.
    Li J, Liu P, Mao H, Wanga A, Zhang X.
    Oncol Rep; 2009 Jun 16; 21(6):1605-10. PubMed ID: 19424643
    [Abstract] [Full Text] [Related]

  • 13. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice.
    Ueda K, Iwahashi M, Matsuura I, Nakamori M, Nakamura M, Ojima T, Naka T, Ishida K, Matsumoto K, Nakamura T, Yamaue H.
    Eur J Cancer; 2004 Sep 16; 40(14):2135-42. PubMed ID: 15341989
    [Abstract] [Full Text] [Related]

  • 14. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
    Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6966-71. PubMed ID: 16203789
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
    Hadaschik BA, ter Borg MG, Jackson J, Sowery RD, So AI, Burt HM, Gleave ME.
    BJU Int; 2008 Jun 01; 101(11):1347-55. PubMed ID: 18384637
    [Abstract] [Full Text] [Related]

  • 16. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
    Yan XD, Li M, Yuan Y, Mao N, Pan LY.
    Oncol Rep; 2007 May 01; 17(5):1163-9. PubMed ID: 17390060
    [Abstract] [Full Text] [Related]

  • 17. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.
    Clin Cancer Res; 2007 Dec 01; 13(23):7191-8. PubMed ID: 18056200
    [Abstract] [Full Text] [Related]

  • 18. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J, Gänge J, Pilz S, Stötzer C, Ohlinger R, Belau A, Lorenz G, Beck JF.
    BMC Cancer; 2006 Jul 11; 6():183. PubMed ID: 16834771
    [Abstract] [Full Text] [Related]

  • 19. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K, Kikuchi Y, Kudoh K, Hirata J, Kita T, Nagata I.
    Jpn J Clin Oncol; 2000 Oct 11; 30(10):446-9. PubMed ID: 11185891
    [Abstract] [Full Text] [Related]

  • 20. Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer.
    Wang Z, Cai L, Wang H.
    Gynecol Oncol; 2005 Mar 11; 96(3):643-50. PubMed ID: 15721406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.